CTRI/2010/091/000223
Completed
Phase 3
A phase 3, single blind, randomized, comparative, multicentric clinical study to evaluate efficacy and safety of FDC of Epalrestat 50 mg + Methylcobalamin 500 mcg with Epalrestat 50 mg in the treatment of patients with Diabetic neuropathy.
Aristo Pharmaceuticals pvt. ltd.0 sites220 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Aristo Pharmaceuticals pvt. ltd.
- Enrollment
- 220
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \> 18 yrs, Type 2 diabetes treated with oral hypoglycemics with evidences of neuropathy, informed consent
Exclusion Criteria
- •no or low score for diabetic neuropathy, other type of neuropathy, other medications, patients with peripheral vascular diseases.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
Comparison of different types of Injectable iron in the treatment of Iron Deficiency AnemiaHealth Condition 1: D509- Iron deficiency anemia, unspecifiedCTRI/2023/01/048725Armed Forces Medical College
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-GBGlaxoSmithKline Biologicals1,220
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-DEGlaxoSmithKline Biologicals1,220
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageVaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).MedDRA version: 18.1Level: PTClassification code 10069613Term: Varicella immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10069628Term: Varicella immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10063315Term: Varicella zoster virus DNA test positiveSystem Organ Class: 100000004848MedDRA version: 18.0Level: LLTClassification code 10046983Term: Varicella zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: PTClassification code 10046980Term: VaricellaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: LLTClassification code 10050331Term: Varicella-like rashSystem Organ Class: 100000004858MedDRA version: 18.0Level: LLTClassification code 10063144Term: Varicella zoster virus serology positiveSystem Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2013-003535-30-EEGlaxoSmithKline Biologicals1,220
Active, not recruiting
Not Applicable
Safety of Hib-MenCY-TT vaccine versus licensed Hib conjugate vaccine, given at 2, 4, 6 and 12 to 15 months of age.Haemophilus influenzae type b and Neisseria meningitidis serogroups C and YMedDRA version: 18.0Level: LLTClassification code 10028911Term: Neisseria meningitidis infection NOSSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10018953Term: Haemophilus influenzae meningitisSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10018952Term: Haemophilus influenzae infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2005-006066-34-Outside-EU/EEAGlaxoSmithKline Biologicals4,429